Vaxart Inc Stock In The News

VXRT Stock  USD 0.54  0.02  3.85%   
Our overall analysis of Vaxart's news coverage and content from conventional and social sources shows investors' bearish mood towards Vaxart Inc. The specific impact of Vaxart news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Vaxart's overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Vaxart headlines in addition to utilizing other, more conventional financial analysis modules. Check out Vaxart Backtesting and Vaxart Hype Analysis.

Vaxart Today Top News and Investor Outlook

Macroaxis News: globenewswire.com
Vaxart to Host Full Year 2024 Business Update and Financial Results Conference Call on March 20
https://www.globenewswire.com/news-release/2025/03/13/3042116/25416/en/Vaxart-to-Host-Full-Year-2024-Business-Update-and-Financial-Results-Conference-Call-on-March-20.html
 Neutral
Macroaxis News: globenewswire.com
Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate
https://www.globenewswire.com/news-release/2025/03/11/3040474/25416/en/Vaxart-Announces-Clinical-Trial-Initiation-of-Norovirus-Oral-Pill-Vaccine-Candidate.html
 Bullish
Macroaxis News: globenewswire.com
Vaxart Announces Publication Demonstrati...
https://www.globenewswire.com/news-release/2025/03/05/3037762/25416/en/Vaxart-Announces-Publication-Demonstrating-the-Immunogenicity-and-Safety-of-its-First-Generation-Oral-Pill-Norovirus-Vaccine-Candidate-in-Elderly-Adults.html
 Bullish
Yahoo News
Oral Vaccine Focused Penny Stock Vaxart Is 'Uniquely Positioned', Analyst Sees Almost 83% Upside
https://finance.yahoo.com/news/oral-vaccine-focused-penny-stock-175740934.html
 Bullish
Yahoo News
Vaxart Bags $453M Worth BARDA-Funded Project, Seeks To Raise $40M Via Equity Offering
https://finance.yahoo.com/news/vaxart-bags-453m-worth-barda-140612681.html
 Bullish
Yahoo News
Election Year Encore: Can 2020’s Top 7 Stock Winners Repeat Their Performance in 2024?
https://finance.yahoo.com/news/election-encore-2020-top-7-203000897.html
 Bullish
Yahoo News
Vaxart Receives $9.27 Million BARDA Proj...
https://finance.yahoo.com/news/vaxart-receives-9-27-million-133000678.html
 Bullish
Yahoo News
Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management
https://finance.yahoo.com/news/vaxart-announces-10-0-million-142500766.html
 Neutral
Yahoo News
Vaxart, Inc. Announces Management Change
https://finance.yahoo.com/news/vaxart-inc-announces-management-change-142200199.html
 Bullish
Yahoo News
Vaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers
https://finance.yahoo.com/news/vaxart-announces-last-subject-dosed-130000047.html
 Neutral

Vaxart Inc Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Vaxart and other traded companies coverage with news coverage. We help investors stay connected with Vaxart headlines for the 15th of March 2025 to make an informed investment decision based on correlating the impacts of news items on Vaxart Stock performance. Please note that trading solely based on the Vaxart Inc hype is not for everyone as timely availability and quick action are needed to avoid losses.
Vaxart's linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Vaxart Inc investors visualize upcoming and past events in order to time the market based on Vaxart Inc noise-free hype analysis.
Vaxart stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Vaxart earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Vaxart that are available to investors today. That information is available publicly through Vaxart media outlets and privately through word of mouth or via Vaxart internal channels. However, regardless of the origin, that massive amount of Vaxart data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Vaxart news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Vaxart relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Vaxart's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Vaxart alpha.

Vaxart Largest EPS Surprises

Earnings surprises can significantly impact Vaxart's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2020-11-12
2020-09-30-0.09-0.080.0111 
2024-03-14
2023-12-31-0.14-0.120.0214 
2023-08-03
2023-06-30-0.18-0.160.0211 
2020-05-12
2020-03-31-0.04-0.020.0250 
2024-10-31
2024-09-30-0.0933-0.060.033335 
2022-05-09
2022-03-31-0.16-0.2-0.0425 
View All Earnings Estimates

Vaxart Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Vaxart Inc Stock. Current markets are strongly bullish. About 93% of major world exchanges and indexes are currently up. See today's market update for more information.
Gurufocus Stories at Macroaxis
11th of March 2025
Acquisition by Phillip Lee of 410000 shares of Vaxart at 0.78 subject to Rule 16b-3
at gurufocus.com 
zacks News
6th of March 2025
Acquisition by Phillip Lee of 410000 shares of Vaxart at 0.78 subject to Rule 16b-3
at zacks.com 
Gurufocus Stories at Macroaxis
5th of March 2025
Vaxart Announces Publication Demonstrating the Immunogenicity and Safety of its ...
at gurufocus.com 
Macroaxis News
3rd of March 2025
Acquisition by Phillip Lee of 410000 shares of Vaxart at 0.78 subject to Rule 16b-3
at MacroaxisInsider 
Macroaxis News
28th of February 2025
Acquisition by Phillip Lee of 410000 shares of Vaxart at 0.78 subject to Rule 16b-3
at MacroaxisInsider 
Macroaxis News
26th of February 2025
Acquisition by Cummings James F. of 90000 shares of Vaxart subject to Rule 16b-3
at MacroaxisInsider 
news
24th of February 2025
Acquisition by Phillip Lee of 410000 shares of Vaxart at 0.78 subject to Rule 16b-3
at thelincolnianonline.com 

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Vaxart in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Vaxart's short interest history, or implied volatility extrapolated from Vaxart options trading.

Additional Tools for Vaxart Stock Analysis

When running Vaxart's price analysis, check to measure Vaxart's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxart is operating at the current time. Most of Vaxart's value examination focuses on studying past and present price action to predict the probability of Vaxart's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxart's price. Additionally, you may evaluate how the addition of Vaxart to your portfolios can decrease your overall portfolio volatility.